Extended Data Fig. 7: Activity of FAAs.

a, Dose response curves (sigmoidal) of the inhibitory activity of lauroyl tryptamine, tryptamine, and lauric acid on P2RY4 in the presence of the native agonist UTP at 2.79 µM (EC80). IC50 > 100 µM for all three compounds. The points were measured in duplicate. b, Dose response curves (sigmoidal) of the stimulatory activity of lauroyl tryptamine, tryptamine, and lauric acid on GPR132. EC50: lauroyl tryptamine = 1.45 µM; lauric acid = 25.2 µM; tryptamine > 100 µM. The points were measured in duplicate. c, Summary table of EC50s and IC50s calculated using data from the DiscoverX cell-based assay. d, Dose response curves (sigmoidal) of the calcium release-based stimulatory activity on EBI2. The error bars are the standard deviations of the three mean quadruplicate values. EC50: lauroyl tryptamine > 20 µM; 7α,25-OHC = 0.002 µM. e, Dose response curves (sigmoidal) of the radioligand binding activity of different compounds on EBI2. The error bars are the standard deviations of the three mean quadruplicate values. f, Dose response curves (sigmoidal) of the calcium release-based inhibitory activity of different compounds on EBI2 in the presence of the native agonist 7α,25-OHC at 3.7 nM (EC80). The error bars are the standard deviations of the three mean quadruplicate values. g, Dose response curves (sigmoidal) of the calcium release-based stimulatory activity of different compounds on EBI2. The error bars are the standard deviations of the three mean quadruplicate values. h, Summary table of EC50 and IC50 from radioligand binding and calcium release assays. NIBR51 and NIBR189 are known EBI2 antagonists. 7α,25-Dihydroxycholesterol (7α,25-OHC), 7β,25-Dihydroxycholesterol (7β,25-OHC), 25-Hydroxycholesterol (25-OHC), cholesterol, and 7β-Hydroxycholesterol (7-OHC) are known EBI2 agonists.